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Abstract
Although stem-cell therapies have been suggested for cardiac-regeneration after myocardial-infarction (MI), key-questions
regarding the in-vivo cell-fate remain unknown. While most available animal-models require immunosuppressive-therapy
when applying human cells, the fetal-sheep being pre-immune until day 75 of gestation has been proposed for the in-vivo
tracking of human cells after intra-peritoneal transplantation. We introduce a novel intra-uterine myocardial-infarction
model to track human mesenchymal stem cells after direct intra-myocardial transplantation into the pre-immune fetal-
sheep. Thirteen fetal-sheep (gestation age: 70–75 days) were included. Ten animals either received an intra-uterine
induction of MI only (n = 4) or MI+intra-myocardial injection (IMI;n = 6) using micron-sized, iron-oxide (MPIO) labeled human
mesenchymal stem cells either derived from the adipose-tissue (ATMSCs;n = 3) or the bone-marrow (BMMSCs;n = 3). Three
animals received an intra-peritoneal injection (IPI;n = 3; ATMSCs;n = 2/BMMSCs;n = 1). All procedures were performed
successfully and follow-up was 7–9 days. To assess human cell-fate, multimodal cell-tracking was performed via MRI and/or
Micro-CT, Flow-Cytometry, PCR and immunohistochemistry. After IMI, MRI displayed an estimated amount of 16105–56105
human cells within ventricular-wall corresponding to the injection-sites which was further confirmed on Micro-CT. PCR and
IHC verified intra-myocardial presence via detection of human-specific b-2-microglobulin, MHC-1, ALU-Sequence and anti-
FITC targeting the fluorochrome-labeled part of the MPIOs. The cells appeared viable, integrated and were found in clusters
or in the interstitial-spaces. Flow-Cytometry confirmed intra-myocardial presence, and showed further distribution within
the spleen, lungs, kidneys and brain. Following IPI, MRI indicated the cells within the intra-peritoneal-cavity involving the
liver and kidneys. Flow-Cytometry detected the cells within spleen, lungs, kidneys, thymus, bone-marrow and intra-
peritoneal lavage, but not within the heart. For the first time we demonstrate the feasibility of intra-uterine, intra-myocardial
stem-cell transplantation into the pre-immune fetal-sheep after MI. Utilizing cell-tracking strategies comprising advanced
imaging-technologies and in-vitro tracking-tools, this novel model may serve as a unique platform to assess human cell-fate
after intra-myocardial transplantation without the necessity of immunosuppressive-therapy.
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Introduction
Stem cells have been repeatedly suggested as a next generation
therapeutic approach for the treatment of heart failure due to
myocardial infarction or cardiomyopathy [1]. Based on various
animal trials, there are increasing numbers of early phase patient
trials that aim to demonstrate the feasibility and potential efficacy
of stem cell-based therapies in the clinical setting [2–6]. However,
despite the plethora of generated data in the field [7], the in-vivo
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cell fate with specific regards to cell retention and engraftment,
survival, and importantly contribution to cardiac regeneration
after stem-cell transplantation into the heart remains to be
elucidated. One major reason is certainly the too rapid translation
from small animal studies or non-comparable large animal studies
(mainly pigs and sheep) to clinical human studies, while only a
systematic evaluation of the early and late stem cell fate will allow
defining the optimal stem cell therapy concept for sustained
cardiac regeneration.
To assess the cell fate including cellular in-vivo bio-distribution,
engraftment and survival after transplantation, a surrogate animal
model is mandatory allowing for sufficient cell tracking in absence
of any immunologic rejection [8–11]. However, with the exception
of gene-modified murine models, the availability of suitable animal
models to assess human stem cell fate and bio-distribution is very
limited. As most available animal models are associated with the
necessity for immunosuppressive therapy when applying human
cells, the clinical relevance of findings obtained from such animal
models is compromised.
The fetal sheep has been suggested to be an optimal animal
model for the assessment of human cell-fate [8–15]. Although the
fetal sheep has a normal functioning immune-system, it is still able
to support human cell engraftment and differentiation if the cells
are transplanted before day 75 of gestation [8–11,16]. Following
ultrasound-guided, intra-peritoneal stem cell transplantation,
previous reports have shown that the fetal sheep is immunolog-
ically tolerant to human skin grafts and to allogenic or xenogenic
stem cells during this ‘‘pre-immune’’ period of development
allowing for a significant engraftment of human cells without the
necessity of immunosuppressive therapy [8,9,16–23]. Taking this
unique advantage of this pre-immune status as well as the large
size and the long life-span into account, the fetal sheep represents
an highly interesting animal model to study human cell-fate
offering experimental opportunities that are not available in
murine models [10,11,16].
In this study and for the first time, we investigated the feasibility
to use the pre-immune fetal sheep model for the assessment of
human stem cell fate after direct intra-myocardial mesenchymal
stem cell transplantation following acute myocardial infarction
with specific attention to cell retention and early bio-distribution
using advanced, imaging-guided cell tracking protocols.
Materials and Methods
Study Animals & Experimental Design
We studied 8 pregnant Pre-Alp ewes between 70 to 75 days’
gestation (term 145 days) with a total of 13 fetal-sheep. Ten
animals either received an intra-uterine induction of MI only
(n = 4) or MI + intra-myocardial injection (IMI; n = 6) using
micron-sized, iron-oxide (MPIO) labeled human mesenchymal
stem cells either derived from the adipose tissue (ATMSCs; n = 3)
or the bone-marrow (BMMSCs; n = 3). Three animals received an
intra-peritoneal injection (IPI; n = 3; ATMSCs; n = 2/BMMSCs;
n = 1) (figure 1). All animals received humane care in compliance
with the ‘‘Principles of Laboratory Animal Care’’ as well as the US
National Institutes of Health guidelines for the care and use of
animals. All procedures were approved by the Institutional Ethics
Committee of the IMM RECHERCHE, Institut Mutualiste
Montsouris, Paris, France [Approval-No 10-18/2010]. Figure 1
summarizes the study design and the animal distribution.
Cell Isolation, Characterization and Labeling
Isolation of human bone marrow derived mesenchymal
stem cells (BMMSCs). After written informed consent and
approval of the institutional review board of the University
Hospital of Zurich, 80 mL of bone marrow was aspirated from the
sternum of a 52 years old male patient using a bone marrow
aspiration syringe with a needle prior to cardiac surgery at the
University Hospital Zurich. BMMSCs were isolated as previously
described [24]. Please see supporting file S1 for further details.
Isolation of human adipose tissue derived mesenchymal
stem cells (ATMSCs). ATMSCs (isolated from a 45 years old
female patient after written informed consent and approval of the
institutional review board of the University Hospital of Zurich)
were generously provided by Dr. Maurizio Calcagni from the
Clinic for Plastic and Reconstructive Surgery, University Hospital
Zurich. The cells were isolated from tissue according to a standard
protocol as described elsewhere [25].
Labeling of human BMMSCs and ATMSCs with CM-DiI
and MPIOs. The cells were first labeled with a fluorescent dye
(CellTracker CM-DiI, Invitrogen, Switzerland) according to the
manufacturer’s instructions. CM-DiI is a lipophilic carbocyanine
tracer and incorporates into membranes. Afterwards the cells were
incubated with culture medium supplemented with 1.63 um-large
encapsulated super-paramagnetic microspheres (MPIOs; Bang
Laboratories, USA) at a final concentration of 2.75 ug/ml iron for
24 to 36 hours as described previously [26]. The particles were co-
labeled with Dragon-green fluorochromes for additional analysis
using fluorescence-based techniques. Please see supporting file S1 for
further details.
The Fetal Sheep Cell Transplantation Model
The fetal sheep model has proven to be an appropriate model
for the assessment of in-vivo cell fate and bio-distribution of
human cells with specific regards to survival and engraftment [10–
12,14,16]. In contrast to other animal models either being
genetically modified (i.e. nude mice) or requiring immunosup-
pressive therapy (xenogenic models such as adult porcine or ovine
models) for the assessment of human stem cells, the fetal sheep has
a normal functioning immune system, but is still able to support
cell engraftment and survival if the cells are transplanted before
day 75 of gestation (term 145 days). Taking advantage of this
‘‘window of opportunity’’ and this ‘‘pre-immune’’ period of
development, this model allows for a significant engraftment of
human cells without the necessity of immunosuppressive therapy
[8–12,14,16].
Operative Procedures
Following overnight fasting, the animals were sedated by
intravenous injection of pentothal (10 mg/kg body weight). The
animals were placed in supine position, intubated, ventilated with
100% oxygen and 1–2% isoflurane and monitored continuously
throughout the entire procedure. No anti-arrhythmic agents were
used during or after the procedure. After the ewes were placed in
dorsal recumbency on the operating table, the uterus was
exteriorized through a maternal midline laparotomy. Following
digital palpation of the fetus, the uterus was opened through a
10 cm incision. The amniotic fluid was collected, stored in a sterile
reservoir and out back into the ewe’s belly to maintain the
temperature until the end of the procedure. While the upper part
of the fetal body remained within the maternal uterine cavity, the
fetal chest was opened via a left-sided mini-thoracotomy (4th
intercostals space). After sharp dissection of the pericardium, the
heart was positioned for an optimal access of the anterior wall and
the apex.
Induction of Myocardial Infarction. After evaluation of
the myocardial vasculature, the left anterior descending coronary
artery (LAD) and the diagonal branches (DB) were identified. To
A Novel Pre-Immune Fetal Sheep Infarction Model
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achieve a sufficient myocardial infarction involving the anterior
wall and the apex, the LAD (6 appropriate diagonal branches)
were suture ligated using a 7/0 suture. Sufficient ligation was
confirmed by instant changes of the regional wall movement and
the colour in the anterior-apical area.
In utero Stem Cell Transplantation
Intra-myocardial Injection. After ligation of the coronary
vessels and an ischemic period of 15–20 min to achieve sufficient
anterior-apical myocardial damage, 6 target zones for cell
transplantation were defined in the left-ventricular anterior area
above the apex. Following careful exposure of the fetal heart, a
mean of 1.2560.306106 cells was slowly injected (60 sec) into the
fetal myocardium using a 29 gauge needle (table 1). The exact
injection sites were carefully documented. After stem cell delivery,
the absence of myocardial bleeding from the injection sites and
cardiac arrhythmia was confirmed before layered closing of the
fetal chest using Vycril sutures. Thereafter, the fetus was carefully
re-positioned with particular regards to the umbilical cord and the
amniotic fluid was re-injected before closing the uterus.
Intra-peritoneal Injection. The procedure was performed
as previously described [20,21,23]. Please see supporting file S1 for
further details.
Post-interventional Care, Follow Up and Animal Harvest
After cell transplantation, the fetal heartbeat was monitored to
confirm post-procedural wellbeing. After confirming stable hemo-
dynamic conditions the anaesthetics were stopped. The ewes were
left to recover and checked daily for their health status and signs of
spontaneous abortion. After 7–9 days post transplantation the
ovine fetuses were delivered abdominally. In brief, the harvest
procedure was as follows: a general anesthesia of the ewe was
initiated with a dose of Sodium Thiopental 10 mg/kg (NesdonalH,
Merial, Lyon, France) which was then maintained with Isoflurane
2% in 100% O2 (Attane
TM Isoflurane, JD Medical, Phoenix,
United States of America) during the surgery. Thereafter,
euthanization was of the ewe was performed by an intravenous
injection of Pentobarbital (Ve´toquinol, Lure, France) and by
intracardiac injection of Dolethal (Ve´toquinol, Lure, France) in the
ovine fetuses.
Next the fetal organs were harvested and processed for further
analysis in compliance with the ‘‘Principles of Laboratory Animal
Care’’ as well as the US National Institutes of Health guidelines for
the care and use of animals. All sacrifice and harvest procedures
were approved by the Institutional Ethics Committee of the IMM
RECHERCHE, Institut Mutualiste Montsouris, Paris, France
[Approval-No 10-18/2010].
Histology & Immunohistochemistry of myocardial
infarction
To assess myocardial infarction, necrosis and cell death,
standardized H&E staining, Masson’s Trichrome and van Giesson
staining was performed. In addition, cleaved Caspase-3 staining
(1:300; Cell Signaling Technology) and TUNEL staining was
performed to further access the presence of apoptosis. Please see
supporting file S1 for further details.
Detection and tracking of CM-DiI+/MPIO+ human
mesenchymal stem cells in the fetal sheep myocardium
To assess the presence and survival of CM-DiI+/MPIO+ human
mesenchymal stem cells a multimodal evaluation strategy was
applied comprising Flow Cytometry, PCR and immunohisto-
chemistry. In brief, the heart was processed as follows: After
cutting away the apical and basal region, the left ventricular,
anterior region (area of injection) was divided into three parts
(each approximately 5 mm65 mm) which were then either
processed freshly for Flow-Cytometry (part 1), snap frozen for
PCR (part 2) or in formaldehyde for immunohistochemistry (part
3). Please see supporting file S1 for further details.
Assessment of intrinsic immune response versus CM-
DiI+/MPIO+ human mesenchymal stem cells in the fetal
sheep myocardium
To assess a potential intrinsic immune response against the
injected CM-DiI+/MPIO+ human mesenchymal stem cells a
Figure 1. Study Design and Animal Distribution.
doi:10.1371/journal.pone.0057759.g001
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detailed immunohistochemical analysis for ovine inflammatory
cells was performed using anti-human antibodies reactive to CD3
(Thermo Scientific, Switzerland), CD20 (Cell marque Lifescreen
Ltd., Switzerland) and CD68 (Biosystems Switzerland AG,
Switzerland) to detect CD3+ T-cells, CD20+ B-lymphocytes and
CD68+ macrophages in the fetal myocardial tissue respectively.
The detection of ovine inflammatory cells using cross-reactive anti-
human antibodies was histologically confirmed on ovine spleen
tissue sections.
Magnetic Resonance Imaging (MRI)
All measurements were performed in a Bruker 4.7T Biospec
47/40 with a gradient strength of 60 mT/m and a slew rate of
1100 T/m/s equipped with a circular polarized 1H mouse whole
body RF coil. The imaging protocol consisted after gradient-echo
(GRE) localizers in 3 spatial directions of 2D T2w fast spin-echo
(FSE) sequences (TR/TE 2500 ms/11 ms; effective TE 33 ms;
echo train length 8; matrix 2566256; FoV 40640 mm; slice
thickness 1 mm; averages 3) in transversal, sagittal and coronal
orientation.
To estimate the amount of MPIO-labelled cells in the
myocardium an in vitro dilution series was performed. Therefore
labelled human MSCs of various counts (16106, 56105, 16105,
56104, 26104) were mixed in each case with 16106 ovine
cardiomyocytes. The cell pellets were embedded in a 2% (w/v)
agarose gel in PBS. The measurement was performed as described
above.
Micro Computed Tomography (Micro CT)
The Micro-CT analysis was performed using a Mirco50
tomographer (Scanco Medical; 90 kVp) with a voxelsize of
1.2 um.
Disclosures and Freedom of Investigation
The equipment and technology used in the study were
purchased using academic funds. The authors had full control of
the design of the study, methods used, analysis of data, and
production of the written report.
Statictical Analysis
Quantitative data are presented as mean 6 standard deviation
(SPSS 17.0, IBM, Somers, NY, USA).
Results
Characterization and MPIO Labeling of human BMMSCs
and ATMSCs
Cell surface proteins of human BMMSCs and human ATMSCs
were evaluated by Flow cytometry. Positive expression of CD44
(mean 6 SD, 93.0%64.3%), CD73 (97.8%60.3%), CD90
(97.5%60.7%), CD105 (84.2%612.5%), and CD166
(94.7%63.3%) was observed for both MSC cell types, while there
was none or only weak expression of CD146 (29.4%614.7%).
Negative levels were detected for CD31 (2.5%63.5%), CD34
(2.8%63.9%) and CD45 (2.5%61.9%) (figure 2A and B). Using
the assays described, human ATMSCs and human BMMSCs
demonstrated their differentiation potential to the adipogenic,
osteogenic and chondrogenic lineages (figure 2C–H).
Successful labeling of human BMMSCs and human ATMSCs
was demonstrated on Prussian Blue staining as well as on
immunofluorescence clearly showing the presence of MPIOs
(figure 3A–G). This was further confirmed on FACS analysis
which also demonstrated an excellent cell labeling efficiency in
excess of 95% (figure 3H).
Surgical Procedures and Induction of myocardial
infarction
The surgical procedure and the induction of myocardial
infarction (MI) could be successfully performed in all animals
(figure 4A–G) scheduled for intra-myocardial stem-cell transplan-
tation or MI only (n = 10, table 1) and was intra-operatively
confirmed by instant changes of the regional wall movement and
the colour in the anterior-apical area (figure 5A). The respective
animals remained hemodynamically stable during the entire
procedure and did not display any major complications (table 1).
In three animals, a short bradycardic episode was present
immediately after ligation of the coronary vessel, but normalized
quickly after a few minutes. In addition, two animals encountered
mild bleeding from the stitching channels of the ligation suture
which self-terminated after a few minutes or was managed with a
hemostatic sealant.
The successful induction of myocardial infarction was also
confirmed on histology and immunohistochemistry. On H&E
staining, the area of myocardial infarction (MI) could be easily
identified showing the typical areas of necrosis when compared to
Table 1. Preoperative & Procedural Data.
Study Animals
Myocardial Infarction
n=4
MI+Intra-myocardial tem Cell
Transplantation =6
Intra-peritoneal tem Cell
Transplantation =3
Cell Type (ATMSCs/BMMSCs) (n) n/a 3/3 2/1
Number of Cells (Mio/106) n/a 1.2560.30 11.7562.81
Injection Volume (ul) n/a 100630 960660
Number of Injections (n) n/a 6 1
Injection Needle (gauge) n/a 29 23
Duration of Procedure (min) 3264 5169 33611
Waiting Time between MI Induction and Cell Injection (min) n/a 1961 n/a
Procedural Mortality (%) 0 (0%) 0 (0%) 0 (0%)
Major procedural complications none none none
Mortality during Follow Up 1 (25%) 2 (33%)* 0 (0%)
*the two animals that died had received human BMMSCs.
Animal Weight (gr) / Size (cm): 331 6 81 / 20 6 2. Overall Survival (%): 10 (77%).
doi:10.1371/journal.pone.0057759.t001
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the surrounding border zone and the healthy myocardium
(figure 5B). In detail, loss of the classical myocardial morphology,
necrotic cell death with the loss of the nuclei and cardiac proteins
as well as the complete loss of entire muscle fibres could be
observed (figure 5B). These findings were further confirmed on
Masson’s Trichrome and van Giesson staining (data not shown).
In addition, also an apoptotic component could be confirmed by
positive staining for activated caspase-3 and TUNEL suggesting a
programmed cell-death in the area of infarction (figure 5C–E).
Intra-myocardial and intra-peritoneal stem cell
transplantation. After induction of MI and the definition of
5–6 target zones in the antero-apical area, intra-myocardial
transplantation either using human BMMSCs (n = 3) or ATMSCs
(n = 3) was successfully performed. All animals tolerated the
procedure very well without any major complications. Two
animals displayed transient arrhythmia during intra-myocardial
stem cell delivery and one animal had minor bleeding from the
injection sites.
The intra-peritoneal transplantation was also carried out
successfully in all animals (n = 3; ATMSCs; n = 2/BMMSCs;
n = 1) and no complications such as bleeding or organ damage
occurred (table 1).
Postoperative Complications and Follow Up
Postoperatively, no major complications occurred in the ewes
and in the fetuses. However, as known from previous reports
[20,21] and despite postoperative monitoring, during follow up,
three (23%) of the fetuses of which one animal underwent
induction of MI only and two animals had received intramyocar-
dial transplantation of BMMSCs died due to spontaneous abortion
and were expelled overnight which was primarily related to the
fragile in-utero approach itself. Table 1 summarizes the preoper-
ative and procedural data.
MRI and Micro CT for Stem Cell Tracking
CM-DiI+/MPIO+ human BMMSCs and ATMSCs could be
successfully detected after stem cell transplantation on high
resolution MRI. In selected animals that had received an intra-
myocardial transplantation after MI, the labeled cell clusters were
clearly visible as areas of strong focal signal loss in the septal and
Figure 2. Characterization of human BMMSCs and ATMSCs. Cell surface proteins of human BMMSCs and ATMSCs were evaluated by flow
cytometric analysis (panel A and B; blue population represents isotype control). Positive expression of CD44, CD73, CD90, CD105, CD166 and none/
weak expression of CD146 was observed for both MSC cell types. Human BMMSCs (C–E) and ATMSCs (F–H) demonstrated their differentiation
potential to the adipogenic (Oil Red O Staining, (C, F)), osteogenic (Alizarin Red S Staining, (D, G)) and chondrogenic lineages (Toluidine Blue Staining, (E,
H)). Scale Bar: 100 um.
doi:10.1371/journal.pone.0057759.g002
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anterior-lateral ventricular wall corresponding to the injection sites
(figure 6A and B). In addition, cells were also detectable in the
costal area, para-vertebral and in the Sinus Phrenico Costalis
indicative that the cells had been distributed in the thorax over
time.
Animals that underwent an intra-peritoneal transplantation
displayed a distribution within the entire intra-peritoneal cavity
involving the liver, the kidneys, the Gerota’s Fascia, intestines as
well as diffuse cell clusters in the surrounding areas (figure 6C–E).
Comparing the dilution series (figure 6F) of MPIO-labeled cells
to the morphological images, the amount of cells in the
myocardium could be estimated to approximately 16105–56105
cells and the cells found in the liver to 56105 cells and around the
kidneys to 56105–16106 cells.
Three dimensional MRI reconstruction confirmed the previous
results on 2D MRI (figure 7A–D) and in selected tissue samples,
the intra-myocardial presence of the iron-oxide labeled cells was
further confirmed high-resolution Micro CT showing several
labeled cell clusters in the myocardium (figure 7E).
Explant Macroscopy
Ten fetuses completed follow-up and could be uneventfully
harvested 7–9 days post transplantation prior to ewes euthaniza-
tion. The fetal heart was carefully excised and the ligation site as
well as the area of myocardial infarction could be easily identified.
In selected animals, the heart appeared to be slightly adhered to
the pericardium and required careful dissection. The other fetal
organs including lungs, liver, kidneys, spleen and others also
appeared to be in good shape and were harvested for further
analysis. Interestingly, most of the animals that had received left-
sided thoracotomy displayed almost complete healing of the
incision already after 7–9 days indicating an accelerated healing
and regeneration potential in the fetal stage.
Assessment of cell fate and early bio-distribution of
injected human BMMSCs and ATMSCs
Detection of CM-DiI+/MPIO+ human ATMSCs and
BMMSCs in fetal tissue by Flow Cytometry. After intra-
myocardial injection, presence of CM-DiI+/MPIO+ human
ATMSCs and BMMSCs could be primarily confirmed within
the heart and within the spleen (table 2, figure 8 A and B). Positive
Figure 3. Labeling of human BMMSCs and ATMSCs with superparamagnetic microspheres (MPIOs; co-labeled with Dragon-green
fluorochromes) and CM-Dil. Successful labeling of human BMMSCs and ATMSCs was demonstrated on Prussian Blue staining before (A and B)
and after MPIO labeling (C and D) as well as on immunofluorescence clearly showing the presence of MPIOs (E–G). After labeling, CM-Dil+/MPIO+
cells displayed excellent cell labeling efficiency in excess of 95% on FACS analysis (H). Scale Bar: 100 um (A and C), 50 um (B, D–G).
doi:10.1371/journal.pone.0057759.g003
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Figure 4. Concept of intra-uterine induction of myocardial infarction and intra-myocardial stem cell delivery into the pre-immune
fetal sheep. The uterus was exteriorized through a maternal midline laparotomy. Following digital palpation of the fetus, the uterus was opened
through a 10 cm incision. The fetal chest was opened via a left-sided mini-thoracotomy (4th intercostal space) (A). After sharp dissection of the
pericardium, the heart was positioned for an optimal access of the anterior wall and the apex (A and D). After evaluation of the myocardial
vasculature, the left anterior descending coronary artery (LAD) and the diagonal branches (DB) were identified (E). To achieve a sufficient myocardial
infarction involving the anterior wall and the apex, the LAD (6 appropriate diagonal branches) were suture ligated using a 7/0 suture (B and F).
Sufficient ligation was confirmed by instant changes of the regional wall movement and the colour in the anterior-apical area (B and F). After ligation
of the coronary vessels, the 5–6 target zones for stem cell delivery were defined. Following careful exposure of the fetal heart, the cells were slowly
injected into the fetal myocardium (C and G). Scale Bar: 5 cm (D–G).
doi:10.1371/journal.pone.0057759.g004
Figure 5. Assessment of intra-uterine induction of myocardial infarction in the pre-immune fetal sheep. Induction of acute myocardial
infarction (MI) was confirmed by instant changes of the regional wall movement and the colour in the anterior-apical area (A; purple discolouration;
white arrow). The area of myocardial infarction (MI) could be easily identified showing the typical areas of necrosis when compared to the
surrounding border zone and the healthy myocardium. In detail, loss of the classical myocardial morphology, necrotic cell death with the loss of the
nuclei and cardiac proteins as well as the complete loss of entire muscle fibres could be observed (B; magnification x2.5). MI was further confirmed on
histology via positive staining for activated caspase-3 (C and D; black arrows) and TUNEL (E; black arrows) in fetal infarcts at 7 days suggesting
programmed cardiomyocyte death within the infracted region. Scale Bar: 500 um (B), 100 um (C–E).
doi:10.1371/journal.pone.0057759.g005
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cells were also found within the bone marrow, the kidneys, lungs
and in the brain (table 2).
In animals that had received intra-peritoneal injection, CM-
DiI+/MPIO+ human ATMSCs and BMMSCs were primarily
identified within the lymphatic organs, including spleen, thymus
and the bone-marrow, while in none of the animals CM-DiI+/
MPIO+ cells were found within the heart (table 2, figure 8C and
D). Positive cells were also detected in the intra-peritoneal lavage
supporting the findings on the MRI analysis. In addition, low
levels of positive cells were distributed in different organs,
including the liver, lungs and kidneys (table 2).
Detection and tracking of CM-DiI+/MPIO+ human
ATMSCs and BMMSCs in the pre-immune fetal sheep
myocardium via PCR Analysis and IHC. Following detection
of CM-DiI+/MPIO+ human ATMSCs and BMMSCs in the fetal
myocardium in the imaging analysis (MRI and Micro CT
scanning) and the FACS assessment, intra-myocardial presence
was further confirmed via PCR analysis using human b-2
microglobulin, a component of the class I antigen complex
(figure 8E). Negative controls from non-injected sheep hearts as
well as human mesenchymal stem cells used as a positive control
clearly confirmed the human specificity of the staining for human
b-2 microglobulin within the fetal myocardium (figure 8E).
Morphologically the cells could be easily identified within the
fetal myocardium, appeared to in physiological shape and viable
(figure 9A–I). The cells had integrated within the fetal heart and
could be found in clusters as well as in the interstitial and
intravascular spaces (figure 9A–I). CM-DiI+/MPIO+ human
ATMSCs and BMMSCs were positive for both human-cell
specific MHC-1 staining (figure 9A and B) as well as anti-FITC
staining detecting the MPIOs within the cytoplasma of the injected
human cells (figure 9C and D). In addition, double positive
staining for the human-specific ALU Sequence in combination
with the anti-FITC staining clearly confirmed the presence of the
injected CM-DiI+/MPIO+ human ATMSCs and BMMSCs
within the fetal myocardium (figure 9E–I).
Assessment of intrinsic immune response versus CM-
DiI+/MPIO+ human ATMSCs and BMMSCs in the fetal
sheep myocardium
Detailed assessment for ovine CD3+ T-cells, CD20+ B-
lymphocytes as well as CD68+ macrophages in the fetal
myocardial tissue did not show a potential intrinsic immune
response against the injected CM-DiI+/MPIO+ human ATMSCs
and BMMSCs (figure 10A–I). The ovine immune cells could be
detected in normal, tissue-specific frequencies and appeared to be
disseminated within the entire fetal myocardium without any sign
of activation due to an immune response against the human cell
graft (figure 10D–F). In particular, neither a T- or B-cell
infiltration into the area of the human cell graft, nor increased
numbers of macrophages in this area could be observed
(figure 10D–F). In contrast, CM-DiI+/MPIO+ human ATMSCs
and BMMSCs could be easily identified morphologically, and by
positive staining for human-specific ALU-sequence as well as the
specific intracellular, brown colour dots given by the iron-oxide
particles clearly indicating that the human cells were in
physiological shape, have kept the MPIOs intra-cellular and have
not been phagocytized by ovine macrophages (figure 10G–I).
Figure 6. Tracking of CM-DiI+/MPIO+ human ATMSCs and BMMSCs on two-dimensional magnetic resonance imaging (MRI). CM-DiI+/
MPIO+ human ATMSCs and BMMSCs could be detected after stem cell transplantation on high resolution 4.7 Tesla MRI. Exemplary image series of an
animal that had received an intra-myocardial injection of CM-DiI+/MPIO+ human ATMSCs the labeled cell clusters were clearly visible as areas of
strong focal signal loss in the anterior-lateral and septal ventricular wall corresponding to the injection sites (A and B; white arrows; axial and sagittal
view; and G; black arrow; showing a non-injected myocardium as respective negative control). Next, an exemplary image series of an animal that
underwent intra-peritoneal injection of CM-DiI+/MPIO+ human BMMSCs displayed the distribution within the entire intra-peritoneal cavity (C–E; white
arrow heads; and H; black arrows; showing a non-injected intra-peritoneal cavity as respective negative control) involving the liver (C; white arrow heads;
axial and view), the kidneys, the Gerota’s fascia (D; white arrow heads; axial view), diffuse cell clusters in the surrounding intra-peritoneal areas (D;
white arrow heads; axial view) as well as between the intestines (E; white arrow heads; sagittal view). Comparing the dilution series (F) of MPIO labeled
mesenchymal stem cells to the morphological images, the amount of cells in the myocardium could be estimated to approximately 16105–56105
cells and the cells found in the liver to 56105 cells and around the kidneys to 56105–16106 cells (A–D and F). (Cell Dilution: 16106 [1], 56105 [2],
16105 [3], 56104 [4], 26104 [5]. Scale Bar: 2.5 cm.
doi:10.1371/journal.pone.0057759.g006
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Discussion
Stem cells have shown great promise as a therapeutic strategy
for the failing heart after myocardial infarction and based on
encouraging preclinical studies [7], there are growing numbers of
clinical pilot trials showing the principal feasibility of stem cell-
based therapies [2–6]. However, the rapid and often too
premature translation into the clinical arena has left many key
questions unanswered with special regards to the in-vivo cell fate
which is fundamental to fully understand the possible beneficial
effect on the diseased heart. In addition, the availability of suitable
animal-models to assess human stem-cell fate and bio-distribution
in-vivo is limited. As most available large animal models require
immunosuppressive therapy when applying human cells to the
myocardium [7] the clinical relevance is compromised and a
surrogate animal model is mandatory to evaluate human stem-cell
fate including bio-distribution, engraftment and survival in the
absence of any xenogenic immune response.
To overcome these limitations, for the first time we demonstrate
the principal feasibility to use a pre-immune fetal sheep intra-
uterine myocardial infarction model for the assessment of human
stem-cell fate after direct intra-myocardial stem-cell transplanta-
tion. Using advanced, imaging-guided cell-tracking protocols
comprising magnetic-resonance imaging (MRI) and micro com-
puted-tomography (Micro CT) as well as in-vitro cell-tracking
tools, this novel model offers an excellent platform to evaluate
human cell-fate in the absence of immunosuppressive therapy.
The pre-immune fetal sheep model has been previously
suggested to represent an appropriate animal model for the
assessment of human cell-fate. Before day 75 of gestation the
immune-system of the fetal sheep is normal functioning, but is still
largely immuno-naı¨ve supporting the engraftment and differenti-
ation of human stem cells without the necessity of immunosup-
pressive therapy that would also compromise the transplanted cells
[8–12,16,17]. In line with that, in our study we did not detect a
potential intrinsic xenogenic immune response after direct intra-
myocardial injection of human mesenchymal stem cells.
While the pre-immune fetal sheep has been primarily used in
the field of experimental haematology to assess in-vivo cell-fate
and bio-distribution after ultrasound-guided, intra-peritoneal stem
cell delivery [9,20–23,27], this is the first report demonstrating the
feasibility of direct intra-myocardial stem-cell transplantation after
myocardial infarction. While previous studies reported a limited
homing to the myocardium after intra-peritoneal stem-cell
transplantation [9,20–23,27] indicating the clear limitations of
this model with regards to myocardial regeneration, our novel
concept of intra-uterine, direct intra-myocardial stem-cell trans-
plantation appears to be more appropriate in the setting of
cardiovascular stem cell therapy concepts and offers a significant
improvement with regards to myocardial cell retention.
In this study, we used an advanced concept of imaging-guided
tracking methodology including MRI/Micro-CT Scanning as well
as multiple analysis tools comprising Flow Cytometry, PCR and
IHC to track human cells in the fetal sheep myocardium. Using
Figure 7. Tracking of CM-DiI+/MPIO+ human ATMSCs and BMMSCs on three-dimensional reconstruction MRI and Micro CT
Scanning. Exemplary three-dimensional reconstruction analysis confirmed labeled cell clusters of human CM-DiI+/MPIO+ ATMSCs after
intramyocardial transplantation in the anterior-lateral and septal ventricular wall (A and B; white arrows; anterior-lateral and septal view). In
addition, labeled cells were also detectable in the costal/para-vertebral area (A and B; white *) and in the Sinus phrenico-costalis (A and B; white #)
indicative that the cells had been distributed in the fetal thorax. Abdominal 3D reconstruction analysis showed labeled cell clusters of CM-DiI+/MPIO+
human BMMSCs following intra-peritoneal injection within and around the liver (C; white arrows; anterior-inferior view) as well as in the anterior the
Gerota’s fascia (D; white arrows; lateral view). The intra-myocardial presence of CM-DiI+/MPIO+ human ATMSCs could be further confirmed showing
several labeled cell clusters in the fetal myocardium on 2-dimensional as well as 3-dimensional high-resolution Micro CT analysis (E). Scale Bar: 2 cm.
doi:10.1371/journal.pone.0057759.g007
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novel micron-sized, Dragon-green fluorochrome labelled iron-
oxide particles (MPIO) that had so far been used in the field of
liver research [28,29], we were able to evaluate human cell-fate
after intra-myocardial stem cell transplantation on MRI which was
then followed by detailed Flow Cytometry, PCR and IHC
assessment highlighting the advantage of the fluorochrome co-
labelled MPIOs. On MRI, the MPIO labeled cell-clusters were
clearly visible within the septal and anterior-lateral ventricular-
wall corresponding to the injection sites. Thereafter, the intra-
myocardial presence was verified on Flow-Cytometry and PCR,
before it was further confirmed on IHC via positive staining for
human-specific MHC-1, ALU-Sequence as well as anti-FITC
detecting the fluorochrome labeled part of the iron-oxide particles.
Considering the initially performed dilution series, the amount of
cells within the myocardium could be estimated to approximately
16105–56105 providing a brief quantitative estimation of cell-
retention after intra-myocardial stem-cell transplantation as a
precondition to explain potential beneficial effects of stem-cell
therapy concepts.
Advanced imaging technologies for stem-cell tracking with
regard to survival, engraftment and differentiation represent a key-
requisite to validate functional effects of cell-based therapy
concepts [30,31]. Various imaging-concepts are currently under
evaluation including MRI imaging with direct cell-labelling of cells
using super-paramagnetic agents, PET- or SPECT-imaging using
radio-nuclides, as well as reporter-genes [30,31]. While each of
these approaches has advantages and disadvantages, most of the
recent large animal-studies applied MRI technology to detect
super-paramagnetic agents as this technique has become an
important endpoint to demonstrate efficacy in clinical pilot studies
[30]. It offers detailed morphologic as well as functional cardiac
information and therefore appears to be an appropriate imaging
tool to comprise both, efficacy evaluation and the capability for
cell-tracking. Current studies aim on refining contrast-agents to
achieve a maximum signal for minimum labelling [30]. While the
lowest cell amount detectable with a conventional MRI scanner
was 105, a recent study highlighted that this threshold of detection
can be further reduced whit the use of high resolution scanners
(11.7-T) that may even allow for single cell tracking [32]. In
addition, preclinical animal studies applying micron- or nano-sized
iron-oxide particles showed the feasibility of non-toxic labelling of
mesenchymal stem cells (MSCs) without compromising their trans-
differentiation capacity [32–35].
On the other hand, it has been described that the main
disadvantage of using super-paramagnetic agents is the fact that
the imaging signal is not directly linked to cell-viability and the
inability to discriminate between vital, labelled cells and particle-
loaded cell-debris or hosting macrophages that may have actively
phagocytised the particles after cell-death significantly confound-
ing a sufficient call tracking analysis [31]. However, utilizing a
detailed in-vitro tissue evaluation and importantly, advanced
super-paramagnetic agents such as micron-sized, Dragon-green
fluorochrome co-labeled iron-oxide particles [28,29,36], we were
able to proof the MRI findings and to confirm the presence of the
transplanted cells within the fetal myocardium. Using specific
antibodies to either detect human cells, the fluorochrome co-
labeled MPIOs or both, we were able to clearly detect the
transplanted cells highlighting the efficacy of this cell-tracking
approach.
Finally, while various stem cell sources are currently under
evaluation for their ability to promote cardiac repair [37–44], in
this study we used human mesenchymal stem cells (MSCs) either
derived from the bone-marrow or from the adipose tissue as they
are considered clinically safe, easily available and immuno-
privileged [45]. In particular, bone-marrow derived MSCs
representing a benchmark cell for cardiovascular stem cell
therapies have been repeatedly used in preclinical animal models
Figure 8. Assessment of cell fate and early bio-distribution of
injected of human ATMSCs and BMMSCs via Flow Cytometry
and PCR analysis. Flow cytometric analysis in an exemplary recipient
after direct intra-myocardial injection (IMI) of human ATMSCs. CM-DiI+/
MPIO+ human ATMSCs were primarily detected within the heart and
within the spleen (A and B). In an animal that had received intra-
peritoneal injection (IPI) of human BMMSCs, CM-DiI+/MPIO+ BMMSCs
were primarily identified within the lymphatic organs, in particular
within spleen, while no CM-DiI+/MPIO+ cells were found within the
heart (C and D). Intra-myocardial presence of CM-DiI+/MPIO+ human
ATMSCs was further confirmed via PCR analysis using human b-2
microglobulin (E), a component of the class I antigen complex.
Negative controls from non-injected sheep hearts as well as human
mesenchymal stem cells used as a positive control clearly confirmed the
human specificity of the staining for human b-2 microglobulin within
the fetal heart: Agarose gel analysis of human b-2 microglobulin (left
panel, A) and b -actin (right panel, B) PCR products. Lane 1: molecular
size marker (100 bp DNA ladder, Genecraft, Germany). Lane 2: human
mesenchymal stem cells as a positive control. Lane 3: ovine fetal heart
after human ATMSCs injection. Lane 4: tissue from sheep heart as a
negative control for the human b-2 microglobulin sequence.
doi:10.1371/journal.pone.0057759.g008
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Table 2. Distribution of CM-DiI+/MPIO+ human mesenchymal stem cells in ovine fetal tissue by Flow Cytometry.
Intra-myocardial Stem Cell Transplantation Intra-peritoneal Stem Cell Transplantation
Tissue Analyzed Detected Analyzed Detected
n n (%) n n (%)
Heart 4 4 (100%) 3 0 (0%)
Brain 4 3 (75%) 3 0 (0%)
Spleen 4 4 (100%) 3 2 (66%)
Kidneys 4 4 (100%) 3 2 (66%)
Lavage 4 0 (0%) 3 3 (100%)
Bone Marrow 2 2 (100%) 3 2 (66%)
Liver 4 1 (25%) 3 1 (33%)
Lung 4 3 (75%) 3 2 (66%)
Thymus 4 1 (25%) 2 2 (100%)
doi:10.1371/journal.pone.0057759.t002
Figure 9. Detection of CM-DiI+/MPIO+ human ATMSCs in the pre-immune fetal sheep myocardium via immunohistochemistry.
Exemplary image series post intramyocardial transplantation of human ATMSCs into the fetal myocardium. Morphologically CM-DiI+/MPIO+ human
ATMSCs could be easily identified within the fetal heart tissue suggesting to be in good shape and viable. The cells appeared to be integrated within
the fetal myocardium and could be found as clusters as well as in the interstitial and intravascular spaces (A–I; black arrows). The cells stained positive
for human specific Major Histo Compatibility Complex 1 (MHC-1) clearly confirming the human origin (A and B; black arrows) and also stained
positive for anti-FITC detecting the Dragon Green fluorochrome labelled MPIOs within the human cells (C and D; black arrows). In addition, double
staining for ALU Sequence and anti-FITC further confirmed the presence of the injected CM-DiI+/MPIO+ human ATMSCs within healthy heart tissue (E
and F; black arrows) as well as in infarcted myocardium (G–I; black arrows) Scale Bar: 100 um (A–C, E, G, H), 50 um (D, F, I).
doi:10.1371/journal.pone.0057759.g009
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[46–49] as well as in clinical pilot trials [2,5,45]. Importantly,
beside their suggested function through multiple paracrine effects
[2] recent reports indicate that bone-marrow MSCs can be
programmed into a cardiac committed stage increasing their
clinical relevance and potential [50]. Similarly, the adipose tissue
also represents a rich source of MSCs being well comparable to
those derived from the bone marrow [51] with regards to the
surface marker profile and the differentiation capacity. Further-
more, due to their abundant availability and the even lesser
invasive access, adipose tissue derived MSCs should be considered
as an attractive and clinically highly relevant stem cell source for
future therapy concepts [52].
There are several limitations in our report that need to be
addressed in further studies: First, since it was the overall aim of
this proof-of-concept study to establish a novel model of intra-
uterine induction of MI and direct intra-myocardial stem cell
transplantation in a technically challenging and very delicate fetal
environment, the number of animals was low and the follow-up
time was relatively short. Therefore, further studies with an
increased number of animals and a longer follow-up are
mandatory in order to address the important aspect of long-term
engraftment and bio-distribution. Secondly, in the context of the
presented multimodal approach for an advanced cell tracking
comprising Flow-Cytometry, PCR and IHC, it is to mention that
the Flow Cytometry results may have been influenced by the
location and size of the harvested cardiac sample as well as the
gating strategy. To address the key aspect of cellular retention
more accurately including absolute number of cells, the analysis of
the entire heart with only a single assessment strategy either using
Flow-Cytometry or qPCR would be necessary. Third, in this study
two different types of human mesenchymal stem cells were used
potentially influencing the study results to some extent. In
addition, and although the cardiovascular differentiation potential
of human mesenchymal stem cells is of particular interest, this was
beyond of this proof-of-concept study. Moreover, besides the
infarction histology, a functional assessment (i.e. with echo) of the
fetal heart after myocardial infarction was not performed in this
first feasibility study. Finally, the MRI analysis was based on T2w
sequences. To further enhance cell number estimation accuracy,
T2w and T2*w relaxation curves of the tissue will be performed.
Figure 10. Assessment of intrinsic immune response versus CM-DiI+/MPIO+ human ATMSCs in the pre-immune fetal sheep
myocardium. Control staining of CD3+ T-cells, CD20+ B-lymphocytes and CD68+ macrophages in ovine spleen tissue (A–C) After direct intra-
myocardial injection of CM-DiI+/MPIO+ human ATMSCs (D–I; black arrows), CD3+ T-cells (D; black arrow heads) CD20+ B-lymphocytes (E; black arrow
head) could be detected in normal, tissue-specific frequencies and appeared to be disseminated within the entire fetal myocardium without any sign
of activation due to an immune response against the human cell graft. In particular, neither a T- or B-cell infiltration into the area of the human cell
graft, nor increased numbers of CD68+ macrophages (F) in this area could be observed. In contrast, CM-DiI+/MPIO+ ATMSCs could be easily identified
morphologically and by positive staining for human-specific ALU-sequence (D–I; black arrows). The human cells were in physiological shape (G and
H; black arrows and black frame) have kept the MPIOs intra-cellular (I; black arrow heads) and have not been phagocytized by ovine macrophages.
Scale Bar: 100 um (A–F), 50 um (G and H) and 20 um (I).
doi:10.1371/journal.pone.0057759.g010
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Conclusions
For the first time we demonstrate the principal feasibility of
direct intra-myocardial stem-cell transplantation following intra-
uterine induction of myocardial infarction in the pre-immune fetal
sheep. Using an advanced cell-tracking strategy comprising state-of-
the-art imaging techniques including magnetic-resonance imaging
(MRI) and micro computed-tomography (Micro CT) as well as
multimodal in-vitro tracking tools, this model offers a unique
platform to evaluate human cell-fate and to track human stem cells
in a relevant large animal-model without the necessity of
immunosuppressive therapy.
Supporting Information
File S1 provides further details on materials and
methods.
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